Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10904102 | 1.00 | CA1 (0.50) | CA1CES2CES1LTA4HFDPS | |
| SCHEMBL31472637 | 0.91 | CES2 (0.57) | CA1CES2CES1MEN1FAAH | |
| SCHEMBL28441934 | 0.91 | CES2 (0.57) | CA1CES2CES1MEN1FAAH | |
| SCHEMBL434439 | 0.91 | CES2 (0.46) | CA1CES2CES1ALDH1A1TP53 | |
| SCHEMBL22115920 | 0.91 | CES2 (0.46) | CA1CES2CES1ALDH1A1TP53 | |
| SCHEMBL22115919 | 0.91 | CES2 (0.46) | CA1CES2CES1ALDH1A1TP53 | |
| SCHEMBL15386609 | 0.91 | CA1 (0.50) | CA1CES2CES1LTA4HFDPS | |
| SCHEMBL2530545 | 0.89 | CA1 (0.45) | CA1CES2LTA4HFDPSMEN1 | |
| SCHEMBL2530546 | 0.89 | CA1 (0.45) | CA1CES2LTA4HFDPSALDH1A1 | |
| SCHEMBL7640394 | 0.89 | BLM (0.48) | CA1CES2CES1LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60184039-A | — | — | None | — | — | JP | disclosed |
| US-20250000088-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4424164-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-118139527-A | Ant control agent and ant control method | 信越化学工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023074396-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | 信越化学工業株式会社 | 2023-05-04 | — | — | WO | disclosed |
| CN-111032663-A | Metal alkoxide compound, thin film-forming material, and method for producing thin film | 株式会社ADEKA | 2020-04-17 | — | — | CN | disclosed |
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2188296-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009029844-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-05 | — | — | WO | disclosed |
| US-4604486-A | PINACOL-TYPE REARRANGEMENT OF SOLFONYLOXY ALCOHOLS IN PRESENCE FO ORGANOALUMINUM COMPOUNDS | TOYO STAUFFER CHEMICAL CO., LTD. (JP) | 1986-08-05 | — | — | US | disclosed |
| JP-S60184039-A | PRODUCTION OF OPTICALLY ACTIVE KETONE | TOYO SUTOUFUAA CHEM:KK | 1985-09-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | WAPL, WDR1, DUSP1 | CA1 1517/4885CES2 2318/4885CES1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.